![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
Orgenesis and TamirBio plan to combine ranpirnase with Bioxomes, which have shown the ability to fuse with cell membranes and deliver an intracellular cargo, in a similar manner to natural exosomes.
Lead Product(s): Ranpirnase
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Orgenesis
Deal Size: $19.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 14, 2020